Last reviewed · How we verify
ACR16
ACR16 is an investigational therapeutic in phase 3 development by Teva, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | ACR16 |
|---|---|
| Also known as | Pridopidine, pridopidine |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published mechanism information, the precise molecular target and pharmacological action of ACR16 cannot be reliably determined. Phase 3 status indicates it has progressed beyond early-stage testing, but the mechanism remains proprietary or undisclosed in available sources.
Approved indications
Common side effects
Key clinical trials
- A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease (PHASE2)
- A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease (PHASE3)
- Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACR16 CI brief — competitive landscape report
- ACR16 updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI